Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.
Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.
复制标题
DOI:
10.1016/j.tips.2014.04.006
复制
发表时间:
2014-07
影响因子:
13.8
通讯作者:
Patel, Sachin
中科院分区:
文献类型:
--
作者:
Hermanson, Daniel J.;Gamble-George, Joyonna C.;Marnett, Lawrence J.;Patel, Sachin
Pharmacologic augmentation of endogenous cannabinoid (eCB) signaling is an emerging therapeutic approach for the treatment of a broad range of pathophysiological conditions. Thus far, pharmacological approaches have focused on inhibition of canonical eCB inactivation pathways, fatty acid amide hydrolase for anandamide and monoacylglycerol lipase for 2-arachidonoylglycerol. Here we review experimental evidence that cyclooxygenase-2-mediated eCB oxygenation represents a third mechanism for terminating eCB action at cannabinoid receptors. We describe the development, molecular mechanisms, and in vivo validation of “substrate-selective” COX-2 inhibitors that prevent eCB inactivation by COX-2 without affecting the prostaglandin generation from arachidonic acid. Lastly, we review recent data on the potential therapeutic applications of substrate-selective COX-2 inhibitors with a focus on neuropsychiatric disorders.
登录
查看更多内容
影响因子:
13.5
作者:
Cinar, Resat;Godlewski, Grzegorz;Liu, Jie;Tam, Joseph;Jourdan, Tony;Mukhopadhyay, Bani;Harvey-White, Judith;Kunos, George
通讯作者:
Kunos, George
影响因子:
2.9
作者:
Crilly MA;Mangoni AA
通讯作者:
Mangoni AA
影响因子:
64.8
作者:
Fu, J;Gaetani, S;Piomelli, D
通讯作者:
Piomelli, D
影响因子:
4.8
作者:
Duggan, Kelsey C.;Walters, Matthew J.;Marnett, Lawrence J.
通讯作者:
Marnett, Lawrence J.
影响因子:
5.3
作者:
Ghilardi, JR;Svensson, CI;Mantyh, PW
通讯作者:
Mantyh, PW